The DOI matches its Crossref record; 106 of the 109 references it cites were found in a registry or an index.
Adenovirus vector-based vaccine for infectious diseases
Open accessAbstract
Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt‐Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
Wickham, T. J., Mathias, P., Cheresh, D. A., & Nemerow, G. R. (1993) · Cell · doi:10.1016/0092-8674(93)90231-e · Cited by 2,199
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, P. B., Lama, J. R., Marmor, M., del Rio, C., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61591-3 · Cited by 1,713
CGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695
Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382
Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225
Cited by
Sorted by citations
Items 101–147 of 147
Shimizu, K. (2024) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b23-00837 · Cited by 1
User-Friendly Replication-Competent MAdV-1 Vector System with a Cloning Capacity of 3.3 Kilobases
Zhang, Z., Guo, X., Hou, W., Zou, X., Wang, Y., Liu, S., & Lu, Z. (2024) · Viruses · doi:10.3390/v16050761 · Cited by 1
Bioproduction and immunogenic evaluation of SARS-CoV-2 prototype vaccine in silkworm BmN cells
Zheng, H., Zhao, H., Xiong, H., Awais, M. M., Zeng, S., & Sun, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134027 · Cited by 1
Lee, Y.-J., Easwaran, M., Jung, Y., Qian, Y., & Shin, H. (2024) · Vaccines · doi:10.3390/vaccines12111247 · Cited by 1
Shimizu, K., Shindou, H., Tomita, K., & Nishinaka, T. (2025) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.24-00177-1 · Cited by 1
The Application of DNA Viruses to Biotechnology
Schieferecke, A. J., Ralph, N. K., & Schaffer, D. V. (2025) · Viruses · doi:10.3390/v17030414 · Cited by 2
Methods to mitigate immune response
Ezeuko, C. C., Efa, B. B., & Matthews, Q. L. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00005-x · Cited by 1
Weiss, F., Kolibius, J., Freitag, P. C., Gantenbein, F., Kipar, A., & Plückthun, A. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200984 · Cited by 1
Advantages and Challenges of Viral Vector Vaccines
Dawre, S., Prajapati, M. K., & Shevalkar, G. B. (2025) · doi:10.1002/9781394271566.ch10 · Cited by 1
Nonreplicating Viral Vectors for Vaccine Delivery
Balar, P. C., & Chavda, V. P. (2025) · Wiley eBooks · doi:10.1002/9781394271566.ch5 · Cited by 1
Okamba, F. R., Etoka‐Beka, M. K., Morabandza, C. J., Loko, S., Nzoussi, B., Tsaty, A. D. P., Elgha, N. B., Pambou, P. S. K., & Etou, A. W. O. (2022) · International Journal of Vaccines and Immunization · doi:10.16966/2470-9948.130
Rani, R., Nayak, M., & Nayak, B. (2023) · Transplant Immunology · doi:10.1016/j.trim.2023.101804
Naidich, G., Santucci, N. E., Pezzotto, S. M., Ceccarelli, E. A., Bottasso, O. A., & Perichón, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1141794
Research Advances in SARS-Cov-2 Vaccination of Bell’s Palsy
余, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134843
Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem
Hassani, S., Poortavakol, M. M., & Sayyadi, M. (2022) · Iranian Journal of Blood and Cancer · doi:10.58209/ijbc.14.4.125
Desenho e avaliação de eficácia de uma vacina de DNA contra o vírus zika em camundongos
Teixeira, F. M. E. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2023.tde-12092023-153200
Immunotherapeutics: Advancing precision medicine in cancer treatment
Chhatrola, S., Vaghela, A. R., Zalavadiya, I., & Raval, K. Y. (2024) · IP International Journal of Comprehensive and Advanced Pharmacology · doi:10.18231/j.ijcaap.2024.003
AN OVERVIEW OF CURRENT VACCCINES FOR THE PROPHYLAXIS OF BACTERICAL INFECTIONS
Božić, D. D., & Bufan, B. (2024) · Preventive Paediatrics · doi:10.46793/pp240214004b
Wang, Y., Zou, X., Guo, X., Zhang, Z., Wang, M., Hung, T., & Lu, Z. (2024) · Genes · doi:10.3390/genes15040467
Development of a new vaccine at the laboratory scale
Bohara, V. S., Bora, N. R., Sevda, S., & Kumar, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15378-5.00006-1
Nshimirimana, J., Kimani, J., Kimotho, J. H., Munyao, M. M., & Nzou, S. M. (2024) · Immuno · doi:10.3390/immuno4020012
Preclinical development of viral vector gene therapies
Newman, M. S., Hudry, E., Brassard, J. A., & Cunningham, J. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13344-2.00003-1
Gene therapy for neurodegenration
Koduru, T. S., Osmani, R. A. M., & Madhuchandra, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28822-7.00027-1
Stubbe, M., Stubbe, H. C., Mai, J., Plank, V., Hofmann, S., Göttig, L., Günther, T., Grundhoff, A. T., Krebs, S., Groitl, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.07.636424
LAVR-289, a New Orally Bioavailable Inhibitor of Adenovirus Replication in vitro and in vivoPreprint
Quentin-Froignant, C., Tollefson, A. E., Cline-Smith, A., Kappler‐Gratias, S., Landrein, N., Roy, V., Agrofoglio, L. A., Tóth, K., Wodrich, H., & Gallardo, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.20.639236
Integrating affinity chromatography in the platform process for Adenovirus purificationPreprint
Wu, Y., Barbieri, E., Smith, W. K., Minzoni, A., Kilgore, R., Chu, W., Daniele, M. A.-A., & Menegatti, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646491
Adenovirus-based strategies for cancer vaccines
Geng, K., & Gillanders, W. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00021-8
Systems of adenoviral gene transfer vectors moving into their fourth generation
Yan, Q., Cull, J. W., Tarbet, E. B., & Staerz, U. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00002-4
Adenovirus vectored veterinary vaccines
Dar, F., Kulanayake, S., Ndlovu, S., Chand, S., Singh, B., & Tikoo, S. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00004-8
Higgins, T. A., Agarwal, P., & Smith, B. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-89821-8.00015-2
Hope Unlocked: Gene Therapy with Viral Vectors and Gene Editing
Thiaville, J. J., Dias, M. S., Kato, S. E. M., Basak, S., Rengarajan, S., Silva, H. P., Rivas, N., & D’Costa, S. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-81787-8_5
Cryo-ET unravels the mystery of Ad5-nCoV vaccines
Liu, C., & Ke, Z. (2025) · Structure · doi:10.1016/j.str.2025.04.006
Vuppu, S., Mishra, T., Mishra, S., Stany, B. K., & Das, A. (2025) · doi:10.1002/9781394271566.ch2
Neurologic Complications of Immunization
Chiriboga, C. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00136-0
Oral Vaccines: A Revolution in Preventive Medicine
Sharma, S., Sharma, R., Kumar, S., Bhardwaj, A., & Dhamija, K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324570125010006
Egyptian Ministry of Agriculture and Land Reclamation, E.-B., Heniedy, A. M., El-Sheridy, N. A., Saleh, N., & Alexandria Directorate of Health Affairs, M. O. H. A. P. (2025) · Trends in Pharmacology and Drug Delivery · doi:10.62184/tpdd.jtpdd110020244
Ma, Q.-W., Li, Z. Y., Zhang, Z.-C., Guo, X., Zou, X., Hung, T., & Lu, Z. (2026) · Methods and Protocols · doi:10.3390/mps9030100
Vecchio, J. A., & Schorey, J. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.24.734229
Comparative analysis of non-clinical and clinical safety assessment of COVID 19 vaccines
Gonin, C., Samuel, C., Kayrouh, C., Chollet‐Martin, S., Salomon, V., Louin, G., & Pallardy, M. J. (2026) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2026.106177
Ma, O. X., Lu, S., Mudrick, H. E., Barry, M. E., French, J. B., Barry, M. A., & Reddy, V. S. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014389
Okumura, F., Tokuoka, S., Nagata, N., Onishi, R., Shiota, A., Sakurai, F., Shimizu, K., & Mizuguchi, H. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107619
One virus—many strategies: type-specific interactions between human adenoviruses and innate immunity
Hanrieder, L., & Schreiner, S. (2026) · Journal of Virology · doi:10.1128/jvi.00204-26
Progress in Protein Nanoparticle Vaccines for Human Viral Diseases
He, Y., Wang, J., Li, J., Shen, D., Mao, J., Zhang, Y., Cao, S., Deng, Y., & Gao, X. (2026) · ACS Omega · doi:10.1021/acsomega.6c03523
Hanifehnezhad, A., Öztop, S., Tavukçuoğlu, E., Tanyeri, Y., Yoyler, E., Gökçe, G., Unal, N., Bozkır, A., Karaoğlu, T., Esendağlı, G., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-59094-6
Engineering Metal Nanomaterials for Precision Genetic Medicine
Zheng, K., & Leong, K. W. (2026) · Advanced Functional Materials · doi:10.1002/adfm.78378
Systemic and Mucosal Immune Responses From Serotype‐Switched Viral‐Vectored Ebola Vaccines
Wiggins, J., Madapong, A., & Weaver, E. A. (2026) · Journal of Medical Virology · doi:10.1002/jmv.71161
Metadata
- Authors
- Sakurai, F., Tachibana, M., & Mizuguchi, H.
- Affiliations
- The University of Osaka (JP)
- Global Center for Medical Engineering and Informatics, The University of Osaka (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Corresponding author
- Sakurai, Fuminori
- Mizuguchi, Hiroyuki
- Venue
- Drug Metabolism and Pharmacokinetics
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 42
- Pages
- 100432
- ISSN
- 1347-4367 (ISSN-L)
- PMC
- PMC8585960
- OpenAlex
- W3213418684
- Cited by
- 148
- References
- 109
- Citations by year
- 2026: 16 · 2025: 42 · 2024: 37 · 2023: 32 · 2022: 21
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Drug Metabolism and Pharmacokinetics (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (20fk0108543h0001)
- Japan Society for the Promotion of Science (20H00664)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- adenoviral vector, vaccine vectors, infectious disease vaccines, gene delivery, innate immunity, immune response, Ebola virus disease, AIDS, COVID-19 pandemic
- MeSH terms
- COVID-19, SARS-CoV-2, Adenoviridae, Communicable Diseases, Genetic Vectors, Humans, Vaccines, Adenovirus Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
